Trials
1 active
2 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Fragile X Syndrome
- Main trialPhase 2
- “This study is a multicenter, double-blind, randomized, placebo-controlled study to assess the safety and tolerability of 3 doses of MRM-3379 in male participants with Fragile X Syndrome ages 16 to 45 (inclusive). In addition, a parallel cohort of participants ages 13 to \<16 will receive open-label MRM-3379. All participants will participate for 12 weeks of treatment. The study is also intended as a proof-of-concept investigation to evaluate whether MRM-3379 can improve FXS symptoms”In the company’s words, NCT07209462 on ClinicalTrials.gov
Other drugs for Fragile X Syndrome
- ZatolmilastTetra Discovery Partners · Phase 3
- CodabakalnerSpinogenix · Phase 2/3
- ZYN002Harmony Biosciences · Phase 2/3
- CTH120Connecta Therapeutics, S.L. · Phase 2
- SRX246Azevan Pharmaceuticals · Phase 2
- S247240Institut de Recherches Internationales Servier (I.R.I.S.) · Phase 2
Coming up1
- Oct 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Oct 2027 | Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) | |
| Phase 1Completed | 8 Jul 2026 | A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM-3379 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026